SCHEMBL17865241

SCHEMBL17865241

Cc1cc(C(C)C)c(C2CO2)c(C(C)C)c1

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.32
LMNA P02545 1/20 0.32
CHRM1 P11229 1/20 0.32
SLC6A2 P23975 1/20 0.32
ADRA1A P35348 1/20 0.32
HTR2B P41595 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19729056 0.83 GABRA1 (0.41)
SCHEMBL17865232 0.75 HTR2B (0.41) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL13385205 0.73 RAPGEF4 (0.35) LMNAHTR2B
SCHEMBL17865231 0.70 TSHR (0.30)
SCHEMBL17865246 0.67 SMN1; SMN2 (0.45)
SCHEMBL20636510 0.66 LMNA (0.42) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL16413144 0.66 TSHR (0.44) CHRM1
SCHEMBL25857321 0.66 TSHR (0.44) CHRM1
SCHEMBL27102760 0.65 KDM4E (0.32) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL19729052 0.65 EIF4A3 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170360760-A1 Inhibitors of Bromodomains ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US disclosed
WO-2016097863-A1 INHIBITORS OF BROMODOMAINS ZENITH EPIGENETICS CORP. (CA) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360760-A1 Inhibitors of Bromodomains BRDT, BRD3, BRPF3 TRPA1 4872/4885LMNA 2745/4885CHRM1 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.